Tamil Nadu

‘Dengue vaccine to be ready by 2020’

Union Minister of State for Health Ashwini Kumar says several drugs set for clinical trials

India is currently working on vaccines to prevent dengue and the Phase 1 clinical trials for one of them is slated to be held in 2020, Ashwini Kumar Choubey, Minister of State for Health, told the Rajya Sabha on Tuesday.

In response to questions raised by another member T.K. Rajendran, Mr. Choubey said DSV4, the vaccine developed by The International Centre for Genetic Biotechnology (ICGEB)-Sun Pharma collaborative venture, is a recombinant vaccine on the Virus-Like Particles (VLP) platform with a tetravalent four-in-one VLP design; expressed in yeast, it elicits antibodies to all four DENV serotypes in a shorter schedule of 0, 1 and 2 months.

The vaccine is expected to move into Phase I clinical trials by 2020, Mr. Choubey said.

The other experiment involves the Panacea Dengue Vaccine, which is a cell culture-derived live attenuated, recombinant, freeze- dried, lyophilized tetravalent vaccine with the seed strain borrowed from the National Institute of Health (NIH), US.

The company has successfully completed preclinical toxicology studies.

The Drug Controller General India had granted permission to conduct clinical Phase I/II studies.

The Serum Institute of India is also developing a cell culture-derived live attenuated, recombinant, freeze-dried, lyophilized tetravalent vaccine with seed strain borrowed from the NIH. Preclinical toxicity study will be initiated soon.

The Minister said there were three global vaccines also currently under way. They are CYD-TDV or Dengvaxia of Sanofi Pasteur, a live attenuated vaccine made of non-structural proteins of YF17D.

The vaccine is recommended in three doses (0/6/12 months) at 9+ years of age and is marketed in more than 18 countries now. The TDV (Takeda) live attenuated vaccine is made from non-structural proteins of DENV2 and recommended in two doses (0/3 months) between 4 and 16 years of age. This vaccine will enter Phase III clinical trials in 2018. The TV003/TV005 (NIH & InstitutoBhutantan) live attenuated vaccine is made from non-structural proteins of DENV 1/3/4. It is recommended as one dose between 2 and 59 years of age. The vaccine will enter Phase III clinical trials in 2018, Mr. Choubey informed.

Providing data on the number of dengue cases reported over three years, he said there had been 225 deaths and around 1.50,482 cases reported till November 30, 2017.

Recommended for you
This article is closed for comments.
Please Email the Editor

Printable version | Jul 2, 2020 5:56:42 AM | https://www.thehindu.com/news/national/tamil-nadu/dengue-vaccine-to-be-ready-by-2020/article21968574.ece

Next Story